Heidelberg ImmunoTherapeutics GmbH   Report issue

For profit Phase 2
Founded: Germany (2016)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2019
NCT04165122
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Heidelberg ImmunoTherapeutics GmbH

Active Ingredients

Drugs in Phase 2 Trials (2)

hdit101 (2 trials)

valaciclovir (Valtrex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Herpes Genitalis (Phase 2)

Herpes Labialis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2